By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > ACE inhibitor > Perindopril

Perindopril

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
6 Min Read
SHARE
4 min read|767 words

What is Perindopril?

Perindopril is an angiotensin-converting enzyme (ACE) inhibitor medication used primarily to treat high blood pressure and heart failure. As part of the ACE inhibitor class, it works by blocking a specific enzyme that causes blood vessels to narrow, helping to relax and widen blood vessels throughout the body. This prescription medication is typically taken once daily and has been shown to reduce cardiovascular events when used as directed by healthcare providers.

Uses

Perindopril is approved for several cardiovascular conditions:

Hypertension (High Blood Pressure): The primary use of perindopril is to lower blood pressure in adults, helping to reduce the risk of stroke, heart attack, and kidney problems associated with elevated blood pressure.

Heart Failure: It is used to treat chronic heart failure, improving the heart’s ability to pump blood effectively and reducing symptoms like shortness of breath and fatigue.

Submit Your Paper
GMJ_Submit_Banner

Coronary Artery Disease: Perindopril may be prescribed to reduce the risk of cardiovascular events in patients with stable coronary artery disease, particularly those who have had previous heart attacks or other cardiac procedures.

Diabetic Nephropathy: The medication helps protect kidney function in diabetic patients by reducing protein in the urine and slowing the progression of kidney disease.

Post-Heart Attack Treatment: It may be used as part of long-term therapy following a heart attack to improve survival rates and prevent future cardiac events.

How it works

Perindopril blocks the action of angiotensin-converting enzyme (ACE), which is responsible for producing angiotensin II, a hormone that causes blood vessels to constrict and promotes sodium retention. By inhibiting this enzyme, perindopril allows blood vessels to remain relaxed and dilated, reducing blood pressure and decreasing the workload on the heart. This mechanism also helps improve blood flow to vital organs and reduces the strain on the cardiovascular system.

Side effects

Common side effects include:

  • Dry cough (occurs in up to 10% of patients)
  • Dizziness or lightheadedness
  • Headache
  • Fatigue or weakness
  • Nausea or stomach upset
  • Back pain
  • Upper respiratory tract symptoms
  • Elevated potassium levels

Serious side effects requiring immediate medical attention:

  • Angioedema (severe swelling of face, lips, tongue, or throat)
  • Severe drop in blood pressure causing fainting
  • Kidney function deterioration
  • Severe hyperkalemia (dangerously high potassium levels)
  • Liver dysfunction or jaundice

Warnings and precautions

Pregnancy: Perindopril is contraindicated during pregnancy, especially in the second and third trimesters, as it can cause serious harm to the developing fetus, including kidney problems and death.

Kidney Disease: Patients with existing kidney problems require careful monitoring, as ACE inhibitors can further impair kidney function, particularly in those with bilateral renal artery stenosis.

Hyperkalemia Risk: The medication can increase potassium levels in the blood, which is particularly dangerous for patients with kidney disease, diabetes, or those taking potassium supplements.

Angioedema History: Individuals who have previously experienced angioedema with ACE inhibitors or have hereditary angioedema should not take perindopril due to increased risk of life-threatening swelling.

Surgery Considerations: Patients should inform their anesthesiologist about perindopril use before any surgical procedures, as it may interact with anesthesia and cause severe blood pressure drops.

Interactions

Potassium supplements and potassium-sparing diuretics: Can lead to dangerously high potassium levels when combined with perindopril.

Nonsteroidal anti-inflammatory drugs (NSAIDs): May reduce the blood pressure-lowering effects of perindopril and increase the risk of kidney problems.

Lithium: ACE inhibitors can increase lithium levels in the blood, potentially leading to lithium toxicity.

Diuretics: May cause excessive blood pressure reduction, especially when starting treatment or increasing doses.

Diabetes medications: Perindopril may enhance the blood sugar-lowering effects of diabetes drugs, requiring dose adjustments.

Aliskiren: Should not be used with perindopril in patients with diabetes or kidney impairment due to increased risk of kidney problems and high potassium.

Salt substitutes containing potassium: Can contribute to elevated potassium levels when used with ACE inhibitors.

Check interactions with the GMJ Interaction Checker

Dosage

For hypertension, the typical starting dose is 4 mg once daily, which may be increased to 8 mg daily based on blood pressure response. For heart failure, treatment usually begins with 2 mg once daily, with gradual increases up to 8-16 mg daily as tolerated. In elderly patients or those with kidney impairment, lower starting doses of 2 mg daily are often recommended. The maximum recommended dose is generally 16 mg per day, though most patients achieve adequate blood pressure control with 4-8 mg daily. Dosage adjustments should always be made under medical supervision, and patients should take the medication at the same time each day for optimal effectiveness.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Perindopril." GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/drug/perindopril/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
UK Releases Rabies Post-Exposure Risk Assessment Tool for Clinical Practice

The UK Department of Health and Social Care has published a standardised…

UK Sets Minimum Age of 11 for Puberty Blocker Clinical Trial in Gender-Questioning Children

The UK has set a minimum age of 11 years for children…

Why Women Choose Freebirth: What Research Reveals About Unattended Childbirth

A growing number of women are choosing unattended childbirth, driven by desire…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Ramipril

By
Prof. Giorgi Pkhakadze
01/06/2026

Lisinopril

By
Prof. Giorgi Pkhakadze
01/06/2026

Captopril

By
Prof. Giorgi Pkhakadze
01/06/2026

Fosinopril

By
Prof. Giorgi Pkhakadze
01/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up